ArticleMolecular cancer2026
CircSPARC promotes esophageal squamous cell carcinoma through an HNRNPC-EPN2 splicing axis that activates Wnt/β-Catenin signaling.
Article in Molecular cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Lactylation-regulated ferroptosis: mechanisms, disease associations, and therapeutic strategies.Archives of pharmacal research · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundPersistent activation of the Wnt/β-catenin signaling pathway is a key driver of esophageal squamous cell carcinoma (ESCC) progression. Circular RNAs (circRNAs) have emerged as critical regulators of oncogenic signaling in cancer. However, how circRNAs contribute to the sustained activation of Wnt/β-catenin signaling in ESCC is poorly defined.
methodsIntegrated analysis of self-sequenced and public circRNA datasets revealed elevated expression of circSPARC in ESCC. The functional effects of circSPARC on cell proliferation, migration, and invasion were evaluated through both in vitro and in vivo assays. RNA pull-down, RNA immunoprecipitation (RIP), alternative splicing analysis, RNA antisense purification (RAP), and cell surface protein biotinylation were used to elucidate the molecular mechanism by which circSPARC mediates aberrant Wnt/β-catenin activation in ESCC.
resultsThis study identifies a circRNA-mediated alternative splicing axis that promotes activation of Wnt/β-catenin signaling and ESCC progression. CircSPARC interacts with HNRNPC, a heterogeneous nuclear ribonucleoprotein involved in RNA processing, to suppress the tumor-suppressive long transcript of epsin 2 (EPN2), thereby impairing clathrin-mediated endocytosis-dependent degradation of the Wnt receptor frizzled 7 (FZD7). This interaction leads to sustained Wnt/β-catenin activation, thus promoting ESCC progression. Conversely, expression of the EPN2 long transcript restores circSPARC silencing-induced inhibition of Wnt/β-catenin signaling and suppresses ESCC cell malignancy both in vitro and in vivo. Clinically, elevated expression of circSPARC in ESCC tissues correlates with poor patient prognosis.
conclusionsThese findings reveal a circSPARC-HNRNPC-EPN2 axis that drives persistent Wnt/β-catenin activation through a mutation-independent mechanism. Targeting this pathway in tumors with high circSPARC expression presents a promising therapeutic strategy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.